These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1394 related items for PubMed ID: 20543764

  • 1. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S.
    Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
    [Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I.
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [Abstract] [Full Text] [Related]

  • 3. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

  • 4. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT, Lin SG, Rauser ME, Kaiser PK.
    Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
    [Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [Abstract] [Full Text] [Related]

  • 6. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
    Chen E, Kaiser RS, Vander JF.
    Retina; 2007 Mar; 27(4):445-50. PubMed ID: 17420696
    [Abstract] [Full Text] [Related]

  • 8. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Mar; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 9. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections.
    Chan CK, Abraham P, Meyer CH, Kokame GT, Kaiser PK, Rauser ME, Gross JG, Nuthi AS, Lin SG, Daher NS.
    Retina; 2010 Feb; 30(2):203-11. PubMed ID: 19952998
    [Abstract] [Full Text] [Related]

  • 10. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
    Inoue M, Arakawa A, Yamane S, Kadonosono K.
    Retina; 2013 May; 33(5):990-7. PubMed ID: 23446653
    [Abstract] [Full Text] [Related]

  • 11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 May; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 12. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
    Baba T, Kitahashi M, Kubota-Taniai M, Oshitari T, Yamamoto S.
    Ophthalmologica; 2012 May; 228(2):102-9. PubMed ID: 22508168
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
    Engelbert M, Zweifel SA, Freund KB.
    Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
    [Abstract] [Full Text] [Related]

  • 14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F, Eid Farah M, Melo GB.
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract] [Full Text] [Related]

  • 16. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
    Tao Y, Jonas JB.
    Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
    [Abstract] [Full Text] [Related]

  • 18. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F, Querques G, Forte R, Terrada C, Coscas G, Souied EH.
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [Abstract] [Full Text] [Related]

  • 19. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
    el Matri L, Chebil A, Kort F, Bouraoui R, Baklouti K, Mghaieth F.
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
    [Abstract] [Full Text] [Related]

  • 20. Long-term effectiveness of intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks in pseudoxanthoma elasticum.
    Finger RP, Charbel Issa P, Schmitz-Valckenberg S, Holz FG, Scholl HN.
    Retina; 2011 Jun; 31(7):1268-78. PubMed ID: 21386758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.